Profile data is unavailable for this security.
About the company
Cybin Inc. is a Canada-based biotechnology company. The Company is focused on progressing Psychedelics to therapeutics by engineering drug discovery platforms, drug delivery systems, formulation approaches and treatment regimens for mental health disorders. Across the various research and development programs, the Company is researching and developing an array of synthetic psychedelic active pharmaceutical ingredients (API) intended to be delivered through drug delivery systems, including sublingual films1, orally disintegrating tablets (ODT)2, via inhalation and via intravenous (IV). Its drug programs include Depressive Disorder (CYB003), Alcohol Use Disorder (CYB003), Anxiety Disorders (CYB004) and Neuroinflammation (CYB005). The Company focuses on the clinical development path for CYB004, the Company's deuterated Phase 1 N,N-dimethyltryptamine (DMT) molecule, for the treatment of anxiety disorders. Its subsidiaries include Cybin Corp., Natures Journey Inc, and others.
- Revenue in CAD (TTM)0.00
- Net income in CAD-58.34m
- LocationCybin Inc100 King Street West, Suite 5600TORONTO M5X 1C9CanadaCAN
- Phone+1 (604) 806-0626
- Fax+1 (604) 806-0626